STAND. COM. REP. NO.  216

Honolulu, Hawaii

                , 2017

RE:   H.B. No. 1132

      H.D. 1

Honorable Joseph M. Souki

Speaker, House of Representatives

Twenty-Ninth State Legislature

Regular Session of 2017

State of Hawaii

Sir:

     Your Committee on Health, to which was referred H.B. No. 1132 entitled:

"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT,"

begs leave to report as follows:

The purpose of this measure is to update the State's Uniform Controlled Substance Act to authorize the prescription or dispensing of drugs including buprenorphine and naloxone to patients for purposes of detoxification treatment and maintenance treatment by properly authorized practitioners, consistent with federal law.  This measure also requires the deposit of all fines collected for violation of the Uniform Controlled Substance Act into the Controlled Substance Registration Revolving Fund, consistent with that Fund's purpose.

Your Committee received testimony in support of this measure from Walgreens Co. and an individual.  Your Committee received comments on this measure from the Department of Public Safety, Department of Health, Department of the Attorney General, and Hawaii Substance Abuse Coalition.  

     Your Committee has amended this measure by:

     (1)  Changing its effective date to July 1, 2090, to encourage further discussion; and

     (2)  Making technical, nonsubstantive amendments for the purpose of clarity and consistency.

     As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 1132, as amended herein, and recommends that it pass Second Reading in the form attached hereto as H.B. No. 1132, H.D. 1, and be referred to your Committee on Judiciary.

Respectfully submitted on behalf of the members of the Committee on Health,

____________________________

DELLA AU BELATTI, Chair